Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
Stefan Suciu(St James's University Hospital), Marc Buyse(Institut des Arts de Diffusion), David Cameron(Corewell Health), Keith Wheatley(Cancer Research UK Clinical Trials Unit), Tai‐Tsang Chen(Bristol-Myers Squibb (United States)), Alexander M.M. Eggermont(University Medical Center Utrecht), Achmad Efendi(University of Brawijaya), Gaetan de Schaetzen(Institut Jules Bordet), Paul Lorigan(Manchester Academic Health Science Centre), Svetomir N. Markovic(Mayo Clinic in Arizona), Natalie Ives(Cancer Research UK Clinical Trials Unit), Claus Garbe(University of Tübingen), Srividya Kotapati(Bristol-Myers Squibb (United States)), John M. Kirkwood(UPMC Hillman Cancer Center)
Cited by 93
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k